30 years of historical data (1995–2024) · Healthcare · Drug Manufacturers - General
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bristol-Myers Squibb Company Ce currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | — | $99M | $187M | $253M | — | — | — | — | — | — | — |
| Enterprise Value | — | $41.0B | $30.2B | $31.8B | — | — | — | — | — | — | — |
| P/E Ratio → | -0.02 | — | 0.02 | 0.04 | — | — | — | — | — | — | — |
| P/S Ratio | — | 0.00 | 0.00 | 0.01 | — | — | — | — | — | — | — |
| P/B Ratio | 0.01 | 0.01 | 0.01 | 0.01 | — | — | — | — | — | — | — |
| P/FCF | — | 0.01 | 0.01 | 0.02 | — | — | — | — | — | — | — |
| P/OCF | — | 0.01 | 0.01 | 0.02 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.85 | 0.67 | 0.69 | — | — | — | — | — | — | — |
| EV / EBITDA | — | 2.13 | 1.68 | 1.64 | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 3.14 | 3.56 | — | — | — | — | — | — | — |
| EV / FCF | — | 2.94 | 2.39 | 2.67 | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Bristol-Myers Squibb Company Ce earns an operating margin of 20.0%. A negative ROE of -39.0% indicates the company is currently destroying shareholder equity. ROIC of 12.4% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.8% | 56.8% | 76.2% | 78.0% | 78.6% | 72.3% | 69.1% | 71.0% | 70.8% | 74.5% | 76.4% |
| Operating Margin | 20.0% | 20.0% | 18.2% | 19.7% | 18.4% | 5.1% | 22.6% | 22.7% | 16.6% | 23.4% | 10.4% |
| Net Profit Margin | -18.5% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.9% | 4.8% | 22.9% | 9.8% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.0% | -39.0% | 26.5% | 18.9% | 18.9% | -20.1% | 10.4% | 38.1% | 7.1% | 29.0% | 11.0% |
| ROA | -9.5% | -9.5% | 8.4% | 6.1% | 6.1% | -7.3% | 4.9% | 22.4% | 3.0% | 13.6% | 5.0% |
| ROIC | 12.4% | 12.4% | 10.1% | 10.5% | 9.0% | 2.0% | 8.7% | 26.5% | 15.6% | 18.1% | 7.2% |
| ROCE | 13.6% | 13.6% | 11.1% | 11.2% | 9.1% | 2.1% | 9.8% | 31.1% | 14.1% | 18.7% | 7.1% |
Solvency and debt-coverage ratios — lower is generally safer
Bristol-Myers Squibb Company Ce carries a Debt/EBITDA ratio of 2.7x, which is moderately leveraged (15% below the sector average of 3.1x). Net debt stands at $40.9B ($51.2B total debt minus $10.3B cash). Interest coverage of 5.0x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.12 | 3.12 | 1.41 | 1.31 | 1.27 | 1.36 | 0.92 | 0.52 | 0.67 | 0.41 | 0.46 |
| Debt / EBITDA | 2.66 | 2.66 | 2.31 | 2.10 | 2.37 | 4.12 | 6.21 | 1.26 | 1.84 | 1.30 | 3.18 |
| Net Debt / Equity | — | 2.49 | 1.02 | 1.02 | 0.88 | 0.98 | 0.68 | 0.03 | 0.21 | 0.15 | 0.30 |
| Net Debt / EBITDA | 2.12 | 2.12 | 1.67 | 1.63 | 1.64 | 2.95 | 4.59 | 0.08 | 0.59 | 0.48 | 2.04 |
| Debt / FCF | — | 2.93 | 2.37 | 2.64 | 2.08 | 2.79 | 4.87 | 0.09 | 0.60 | 1.51 | 4.25 |
| Interest Coverage | 4.96 | 4.96 | 7.03 | 7.39 | 6.40 | 1.53 | 9.01 | 27.97 | 17.60 | 27.18 | 9.40 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.25x means Bristol-Myers Squibb Company Ce can comfortably meet its short-term obligations, though there is limited excess liquidity.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | 1.25 | 1.43 | 1.25 | 1.52 | 1.58 | 1.60 | 5.22 | 1.55 | 1.55 | 1.30 |
| Quick Ratio | 1.15 | 1.15 | 1.31 | 1.14 | 1.43 | 1.47 | 1.37 | 4.51 | 1.43 | 1.41 | 1.15 |
| Cash Ratio | 0.46 | 0.46 | 0.55 | 0.42 | 0.79 | 0.87 | 0.67 | 5.22 | 0.71 | 0.48 | 0.30 |
| Asset Turnover | — | 0.52 | 0.47 | 0.48 | 0.42 | 0.36 | 0.20 | 2.12 | 0.62 | 0.58 | 0.52 |
| Inventory Turnover | 8.16 | 8.16 | 4.02 | 4.33 | 4.74 | 5.68 | 1.88 | 5.48 | 5.20 | 3.99 | 3.20 |
| Days Sales Outstanding | — | 84.12 | 123.79 | 110.21 | 98.49 | 88.42 | 107.29 | 92.98 | 110.68 | 104.14 | 94.75 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bristol-Myers Squibb Company Ce pays a dividend yield of 100.0%.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — | — |
| Payout Ratio | — | — | 59.1% | 73.2% | 62.9% | — | 77.9% | 52.8% | 255.9% | 57.1% | 152.5% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 4288.9% | 2500.0% | — | — | — | — | — | — | — |
| FCF Yield | — | 14037.0% | 6764.5% | 4718.3% | — | — | — | — | — | — | — |
| Buyback Yield | — | 0.0% | 100.0% | 100.0% | — | — | — | — | — | — | — |
| Total Shareholder Yield | — | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $2.0B | $2.1B | $2.1B | $2.2B | $2.3B | $1.7B | $1.6B | $1.7B | $1.7B | $1.7B |
Compare CELG-RI with 4 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CELG-RIYou | — | -0.0 | — | — | 56.8% | 20.0% | -39.0% | 12.4% | 2.7 |
| LLY | $942B | 89.9 | 50.5 | 2273.1 | 81.3% | 38.9% | 84.3% | 33.7% | 1.7 |
| JNJ | $599B | 42.9 | 20.7 | 30.2 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
| AZN | $323B | 63.7 | 17.8 | 27.5 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
| BMY | $127B | -14.1 | 8.7 | 9.1 | 56.8% | 20.0% | -39.0% | 12.4% | 2.7 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CELG-RI stacks up against sector leader Eli Lilly and Company.
Start ComparisonBristol-Myers Squibb Company Ce's current P/E ratio is -0.0x. The historical average is 0.0x.
Bristol-Myers Squibb Company Ce's return on equity (ROE) is -39.0%. The historical average is 26.0%.
Based on historical data, Bristol-Myers Squibb Company Ce is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.
Bristol-Myers Squibb Company Ce's current dividend yield is 100.00%.
Bristol-Myers Squibb Company Ce has 56.8% gross margin and 20.0% operating margin. Operating margin between 10-20% is typical for established companies.
Bristol-Myers Squibb Company Ce's Debt/EBITDA ratio is 2.7x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.